Holen Sie sich die Stockscreener-App
6.10
0.99%
0.06
Vorhandelsmarkt:
6.15
0.05
+0.82%
Schlusskurs vom Vortag:
$6.04
Offen:
$6.18
24-Stunden-Volumen:
175.74K
Relative Volume:
0.93
Marktkapitalisierung:
$263.97M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-293.42M
KGV:
-0.2276
EPS:
-26.8031
Netto-Cashflow:
$-13.51M
1W Leistung:
-21.59%
1M Leistung:
-2.09%
6M Leistung:
+181.76%
1J Leistung:
+229.73%
1-Tages-Spanne:
$6.0475
$6.479
1-Wochen-Bereich:
$5.73
$8.3828
52-Wochen-Spanne:
$1.15
$12.46
Minerva Neurosciences Inc Stock (NERV) Company Profile
Firmenname
Minerva Neurosciences Inc
Sektor
Branche
Telefon
617-600-7373
Adresse
1500 DISTRICT AVENUE, BURLINGTON, MA
Compare NERV vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NERV
Minerva Neurosciences Inc
|
6.10 | 263.97M | 0 | -293.42M | -13.51M | -26.80 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Minerva Neurosciences Inc Stock (NERV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-14 | Eingeleitet | BTIG Research | Buy |
| 2019-10-02 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-09-25 | Eingeleitet | Chardan Capital Markets | Buy |
| 2019-09-18 | Eingeleitet | William Blair | Outperform |
| 2019-05-31 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-09-01 | Eingeleitet | Citigroup | Buy |
| 2017-03-06 | Fortgesetzt | Jefferies | Buy |
| 2016-05-12 | Fortgesetzt | Jefferies | Buy |
Alle ansehen
Minerva Neurosciences Inc Aktie (NERV) Neueste Nachrichten
Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026 - Investing News Network
Schizophrenia drug combo showed no safety issues as Phase 3 starts - Stock Titan
Market Overview: Can Minerva Neurosciences Inc continue delivering strong returns2026 Catalysts & High Conviction Buy Zone Picks - baoquankhu1.vn
Minerva Neurosciences Touts Roluperidone Data, FDA-Aligned Trial Plan for Schizophrenia Symptoms - MarketBeat
[EFFECT] Minerva Neurosciences, Inc. SEC Filing - Stock Titan
Minerva Neurosciences, IncCommon Stock (NQ: NERV - The Chronicle-Journal
HC Wainwright Has Bullish Forecast for NERV Q1 Earnings - MarketBeat
Minerva Neurosciences shareholders approve key governance measures - MSN
What is HC Wainwright's Forecast for NERV Q1 Earnings? - MarketBeat
Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum - Investing News Network
NERV: HC Wainwright & Co. Raises Price Target to $7.00, Maintains Neutral Rating | NERV Stock News - GuruFocus
H.C. Wainwright raises Minerva Neurosciences price target on trial design By Investing.com - Investing.com Canada
Minerva Neurosciences: Q4 Earnings Snapshot - theheraldreview.com
Minerva Neurosciences (NERV) Advances Toward Phase 3 Trial with FDA Support - GuruFocus
Minerva Neurosciences Announces $80M Financing and Plans Phase 3 Trial for Roluperidone in Schizophrenia with Results Expected 2H 2027 - Minichart
Minerva Neurosciences (NASDAQ:NERV) Issues Quarterly Earnings Results - MarketBeat
Minerva Neurosciences (NERV) registers $200M shelf for stock, debt and warrants - Stock Titan
Minerva Neurosciences, Inc (NERV) Reports Q4 Earnings - AlphaStreet
Minerva Neurosciences: Fourth Quarter Financial Overview - Bitget
Minerva Neurosciences Q4 & 2025 Financials: Annual Loss of $293.4MNews and Statistics - IndexBox
Minerva Neurosciences 10-K: Revenue $0, EPS (34.67) on large net loss - TradingView
Minerva Neurosciences Q4 net loss widens on non-cash financing charges - TradingView
Minerva Neurosciences Reports $283.7M Q4 Net Loss; $82.4M Cash at Year-End - TradingView
Minerva Neurosciences Reports Q4 and Full-Year 2025 Financial Results and Updates on Roluperidone Development for Schizophrenia Treatment - Quiver Quantitative
BRIEF-Minerva Neurosciences Q4 Net Income USD -283.668 Million - TradingView
Minerva readies 2026 trial for drug aimed at schizophrenia’s ‘negative’ symptoms - Stock Titan
[144] Minerva Neurosciences, Inc. SEC Filing - Stock Titan
NERV SEC FilingsMinerva Neurosci 10-K, 10-Q, 8-K Forms - Stock Titan
Minerva Neurosciences to Participate in The Citizens Life Sciences Conference - The Manila Times
Biotech CEO to present CNS disorder therapies at Miami conference - Stock Titan
Fed Meeting: Can Minerva Neurosciences Inc continue delivering strong returnsQuarterly Earnings Report & Proven Capital Preservation Tips - baoquankhu1.vn
Minerva Neurosciences (NASDAQ:NERV) Upgraded to Hold at Wall Street Zen - MarketBeat
Is Minerva Neurosciences Inc. in a consolidation phaseMarket Weekly Review & Risk Controlled Swing Alerts - mfd.ru
Minerva Neurosciences (NASDAQ:NERV) Shares Pass Above 50 Day Moving AverageHere's What Happened - MarketBeat
Weekly Earnings: Can Minerva Neurosciences Inc be recession proofTrade Risk Summary & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Is Minerva Neurosciences Inc. stock showing strong momentumGold Moves & Fast Moving Trade Plans - mfd.ru
Balyasny Asset Management L.P. Acquires Significant Stake in Min - GuruFocus
Balyasny Asset Management L.P. Acquires Significant Stake in Minerva Neurosciences Inc. - GuruFocus
Minerva Neurosciences Inc expected to post a loss of 30 cents a shareEarnings Preview - TradingView
Coastlands (NASDAQ: NERV) reports 9.99% stake via convertible preferred/warrants - Stock Titan
Is Minerva Neurosciences Inc. in a long term uptrendTake Profit & Safe Entry Zone Tips - mfd.ru
Aug Swings: What drives MODVs stock priceJuly 2025 Earnings & Accurate Intraday Trading Signals - baoquankhu1.vn
Balyasny discloses 4.33M-share Minerva Neurosciences (NERV) position - Stock Titan
Is Minerva Neurosciences Inc. stock attractive for growth ETFs2025 Growth vs Value & Accurate Buy Signal Notifications - mfd.ru
Minerva Neurosciences (NERV) to Release Earnings on Tuesday - MarketBeat
Minerva Neurosciences, Inc.'s (NASDAQ:NERV) market cap touched US$271m last week, benefiting both retail investors who own 55% as well as institutions - simplywall.st
Institutions profited after Minerva Neurosciences, Inc.'s (NASDAQ:NERV) market cap rose US$27m last week but individual investors profited the most - Yahoo Finance
Will Minerva Neurosciences Inc. (4MNA) stock see valuation expansionWeekly Trend Recap & Proven Capital Preservation Tips - mfd.ru
Minerva Neurosciences Inc (NERV) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Minerva Neurosciences (NASDAQ:NERV) Stock Price Passes Above 50-Day Moving AverageWhat's Next? - MarketBeat
Minerva Neurosciences Expands Board Amid Fundraising Effort - MSN
Finanzdaten der Minerva Neurosciences Inc-Aktie (NERV)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):